Patents by Inventor Douglas Howell

Douglas Howell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8501918
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: August 6, 2013
    Assignee: Cytologic, Inc.
    Inventor: Mark Douglas Howell
  • Publication number: 20110201986
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 18, 2011
    Applicant: CYTOLOGIC, INC.
    Inventors: Mark Douglas Howell, Cheryl Lynn Selinsky, Leland Charles Leber
  • Publication number: 20100247822
    Abstract: A multilayer film includes at least an abuse layer that is laser scored, and a sealant layer that has discrete weakened portions, due to the laser scoring. The multilayer film may have a tensile strength of between about 0.40 and 2.5 pounds per 10 millimeters at the location of the one or more weakened portions. In certain aspects, the tensile strength of the multilayer film is between about 7 and 14 pounds per inch at the location of the laser scoring on the abuse layer. Also, a package is provided that is formed from one or more multilayer films having a scored abuse layer and a sealant layer with weakened portions that allow steam and/or pressure to be vented from the package during heating. Optionally, the abuse layer includes a shallow scoring portion to provide an easy-open feature. For instance, the package may be used to cook frozen foods contained in the package, such as in a microwave oven.
    Type: Application
    Filed: February 2, 2010
    Publication date: September 30, 2010
    Inventors: Evan Michael Ziolkowski, Scott Douglas Howells, Gregory William Kokke, Brian Douglas
  • Publication number: 20090227750
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.
    Type: Application
    Filed: February 11, 2009
    Publication date: September 10, 2009
    Inventor: Mark Douglas Howell
  • Publication number: 20080275376
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.
    Type: Application
    Filed: July 16, 2008
    Publication date: November 6, 2008
    Inventors: Mark Douglas Howell, Cheryl Lynn Selinsky, Leland Charles Leber
  • Patent number: 7370904
    Abstract: A cover assembly for a vehicle carried open top container wherein a cover is connected at one end to a vertically adjustable tower and an opposite end to a cross member connected to a pair of pivot arms that are mounted at their lower ends to be pivoted by at least one hydraulic actuator that is mounted to the vehicle intermediate opposite ends of the container and adjacent the bottom thereof. An effective length of each pivot arm may be adjusted and locked in adjusted position.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: May 13, 2008
    Assignee: McNeilus Truck and Manufacturing, Inc.
    Inventors: Robert A. Wood, Jr., Douglas Howell
  • Publication number: 20080075690
    Abstract: Provided is a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partners such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitors from the biological fluids. Particularly useful is an adsorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.
    Type: Application
    Filed: September 22, 2006
    Publication date: March 27, 2008
    Inventor: Mark Douglas Howell
  • Publication number: 20070222253
    Abstract: A cover assembly for a vehicle carried open top container wherein a cover is connected at one end to a vertically adjustable tower and an opposite end to a cross member connected to a pair of pivot arms that are mounted at their lower ends to be pivoted by at least one hydraulic actuator that is mounted to the vehicle intermediate opposite ends of the container and adjacent the bottom thereof. An effective length of each pivot arm may be adjusted and locked in adjusted position.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 27, 2007
    Inventors: Robert Wood, Douglas Howell
  • Publication number: 20050273150
    Abstract: A stent delivery system for positioning a first and second stent the first and second branch lumens of a bifurcation. The stent delivery system includes stent introducers and a sheath or catheter having a frangible wall. A method of delivering stents to anatomies such as bifurcated ducts or vessels.
    Type: Application
    Filed: March 31, 2005
    Publication date: December 8, 2005
    Inventors: Douglas Howell, William Gibbons, Matthew Carter, Victor Clark
  • Publication number: 20050084831
    Abstract: A training system uses a mechanical mock-up with electrically conductive probe points connected to electronically readable memories, and a simulated diagnostic tool to interface with a system or machine simulation for the purpose of operation, maintenance or procedure training. When a probe of a simulated diagnostic tool comes into contact with a probe point of the mechanical mock-up, the electronically readable memory supplies a unique identifier code that is communicated by the simulated diagnostic tool to the simulation to indicate the contact of the probe with the corresponding probe point. Complex wiring connections between the mechanical mock-up and a computer that runs the simulation are eliminated and construction of the training system is significantly simplified.
    Type: Application
    Filed: October 17, 2003
    Publication date: April 21, 2005
    Inventors: Robert Ison, Christopher Conlon, Douglas Howell, David Allen, Mark Reeve-Fowkes, Laurence Norman, Stephen Taylor
  • Publication number: 20020119147
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.
    Type: Application
    Filed: February 7, 2002
    Publication date: August 29, 2002
    Applicant: CytoLogic, LLC
    Inventors: Mark Douglas Howell, Cheryl Lynn Selinsky, Leland Charles Leber
  • Patent number: 6379708
    Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.
    Type: Grant
    Filed: November 20, 1999
    Date of Patent: April 30, 2002
    Assignees: Cytologic, LLC, Colorado State University Research Foundation
    Inventors: Mark Douglas Howell, Cheryl Lynn Selinsky, Leland Charles Leber